title: Blood pressure lowering efficacy of alpha blockers for primary hypertension.
abstract: BACKGROUND
  Alpha blockers are occasionally prescribed for hypertension so it is important to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE).
  
  
  OBJECTIVE
  To quantify the dose-related systolic and/or diastolic BP lowering efficacy of alpha blockers versus placebo in the treatment of primary hypertension.
  
  
  METHODS
  We searched CENTRAL (The Cochrane Library 2009, Issue 1), MEDLINE (1950 to April 2009), EMBASE (1980 to April 2009) and reference lists of articles.
  
  
  METHODS
  Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of fixed-dose monotherapy with an alpha blocker compared with placebo for a duration of 3 to 12 weeks in patients with primary hypertension.
  
  
  METHODS
  Two authors independently assessed the risk of bias and extracted data. Study authors were contacted for additional information. WDAE information was collected from the trials.
  
  
  RESULTS
  Only 10 trials evaluated the dose-related trough BP lowering efficacy of 4 different alpha blockers in 1175 participants with a baseline BP of 155/101 mm Hg. The data do not suggest that any one alpha blocker is better or worse at lowering BP. The best but unsatisfactory estimate of the trough BP lowering efficacy for alpha blockers is -8/-5 mmHg.
  
  
  CONCLUSIONS
  Based on the limited number of published RCTs, the BP lowering effect of alpha blockers is modest; the estimate of the magnitude of trough BP lowering of -8/-5 mmHg is likely an overestimate. There are no clinically meaningful BP lowering differences between different alpha blockers. The review did not provide a good estimate of the incidence of harms associated with alpha blockers because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.
authors.affiliation: Peninsula Technology Assessment Group (PenTAG), Peninsula College of Medicine & Dentistry, University of Exeter, Noy Scott House, Barrack Road, Exeter, Devon, UK, EX2 5DW.
authors.forename: Balraj S
authors.initials: BS
authors.lastname: Heran
authors.forename: Brandon P
authors.initials: BP
authors.lastname: Galm
authors.forename: James M
authors.initials: JM
authors.lastname: Wright
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents